AR and triple-negative breast carcinoma: In recent years, studies have found that the expression of AR is positive in >two-thirds of the triple negative breast cancer patients,[6,7] the abnormal expression of androgen receptors in breast cancer tissue may be associated with invasion and migration of breast cancer,[8] and hormone therapy can significantly inhibit the proliferation of cancer cells, meanwhile, it can promote cancer cell apoptosis by blocking androgen receptors,[8–11] all these studies prompt AR may as a potential target TNBC treatment.